Author Archives: admin

Fate Therapeutics Receives FDA Clearance of IND for FT819 in B-Cell Malignancies – OncLive

By adminJuly 22, 2020Induced Pluripotent Stem Cells

The FDA has cleared an investigational new drug application (IND) for the first-of-its-kind, off-the-shelf CAR T-cell product FT819, which targets CD19-positive malignancies, according to an announcement from Fate Therapeutics, the drugs co-developer.1

The biopharmaceutical company plans to evaluate the product as a treatment for patients with relapsed/refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and non-Hodgkin lymphoma (NHL).

"The clearance of our IND application for FT819 is a ground-breaking milestone in the field of cell-based cancer immunotherapy. Our unique ability to produce CAR T cells from a clonal master engineered iPSC line creates a pathway for more patients to gain timely access to therapies with curative potential, Scott Wolchko, president and chief executive officer of Fate Therapeutics, stated in a recent press release.

As the first CAR-T cell therapy created from cell clonal master-induced pluripotent stem cell (iPSC) line, FT819 can be mass-produced and delivered off the shelf to offer broader access to the treatment. This CAR T-cell product was also developed to improve the safety and efficacy of this modality, and address limitations linked with the patient- and donor-derived products that are currently available, according to Fate Therapeutics.

The treatment is the result of a collaborative effort between a group of investigators led by Michael Sadelain, MD, PhD, the director of the Center for Cell Engineering and head of Gene Expression and Gene Transfer Laboratory at from Memorial Sloan Kettering Cancer Center and Fate Therapeutics.

Four years ago, we first set out under our partnership with Memorial Sloan Kettering led by Dr. Michel Sadelain to improve on the revolutionary success of patient-derived CAR T-cell therapy and bring an off-the-shelf paradigm to patients, and we are very excited to advance FT819 into clinical development, Wolchko added.

In the development of the product, investigators incorporated 1XX CAR signaling domain in an effort to extend T-cell effector function without inducing exhaustion. Additionally, CAR transgene was inserted directly into the T-cell receptor alpha constant (TRAC) locus, which is believed to encourage uniform CAR expression and amplify T-cell potency. Notably, the therapy was also designed to result in the complete bi-allelic disruption of T-cell receptor expression to prevent graft-versus-host disease (GVHD), a notable complication that is known to occur with allogeneic T-cell therapy.

Preclinical data presented during the 2020 AACR Virtual Meeting II showed that FT819 possessed a uniform product profile of 95% CAR+, TCR-, CD45+, CD7+, and CD3+ with most of the CD8 T cells expressing CD8.2 The global gene expression profile of the product showcased high similarity to primary CD19-targeted CAR T cells, thus solidifying its identity as a T lymphocyte, according to the study authors.

Functional assessment revealed strong antigen-specific cytolytic activity against leukemia and lymphoma cell lines (P = .0004) with the product. On-target, off-tumor cytolysis of CD19-positive B cells were confirmed in mixed lymphocyte reaction assay. Moreover, FT819 proved to be unable to produce a GVH response in a co-culture assay with anti-TCR crosslinking antibodies. Furthermore, FT819 was shown to control tumor growth (P = .0003 at day 21) in disseminated leukemia xenograft mouse studies. The product also showed sustained bone marrow localization for 45 days following treatment in a systemic administered leukemia model.

Collectively, these studies demonstrate that FT819 is a potent, homogenous CAR19 T-cell product candidate and can be potentially effectively used off-the-shelf in the treatment of B-cell malignancies, the investigators concluded.

In a planned multicenter phase 1 trial, investigators will identify the maximum-tolerated dose of FT819, as well as the clinical activity and safety of the product in 297 patients with B-cell malignancies, including CLL, ALL, and NHL. Notably, each indication will enroll independently and 3 doses of FT819 will be examined: a single dose of the product (regimen A), a single dose of FT819 in combination with IL-2 cytokine support (regimen 2), and 3 fractionated doses of FT819 (regimen C). Dose-expansion cohorts comprised of up to 15 patients for each indication and regimen can be used to further examine the clinical activity of the CAR T-cell product.

Originally posted here:
Fate Therapeutics Receives FDA Clearance of IND for FT819 in B-Cell Malignancies - OncLive

‘Missing link’: Bayer, Morningside help catapult a new kind of delivery tech to cell and gene therapy – Endpoints News

By adminJuly 22, 2020Stem Cell Clinic

Robert Millman co-founded and led Semma Therapeutics as CEO while also a managing director of MPM Capital. By the time he left the stem cell therapy pioneer two years before it would be sold to Vertex he had left VC life behind.

Instead, he went around scouting new technologies, visiting with tech transfer offices and academics in the Boston/Cambridge area to find worthy ideas that could benefit from his IP expertise.

And he found quite a few.

One of them is Vesigen Therapeutics, which is launching with $28.5 million to turn a new class of extracellular vesicles into packaging and delivery tools for a variety of cargos mRNA, Cas9, base editors, PROTACs, you name it.

The barrier to being a drug company right now is not technology or targets, he told Endpoints News. Theres plenty of targets, theres plenty of technology, but theres no way of getting the two of those into a patient.

Vesigens platform stems from scientific co-founder and Harvard professor Quan Lus work on ARMMs, or arrestin domain-containing protein 1 [ARRDC1]-mediated microvesicles. As he wrote in Nature Communications in March 2018, ARMMs are distinct from exosomes, in that they lend themselves to more controlled production and cargos that can be recruited into the vesicle during the process of manufacturing rather than put together after the fact.

I dont understand really why a whole lot of venture firms didnt jump on it at the time, Millman said. I think its because most were focused on exosomes and just thought that this was another exosome company, and there was already Codiak and Evox.

But Lu showed in his paper delivery of function p53 protein to an p53 deficient animal and restoring p53 activity: To me it was revolutionary.

And compared to the current workhorses of genetic medicines such as viral vectors and lipid nanoparticles, ARMMs promise to package bigger and more varied payloads, get into more organs, and stay in circulation longer without triggering toxicity.

Faced with the Willy Wonka-like range of possibilities, Millman said the top order right now for his team of seven is to figure out a manufacturing setup that would load the cargos efficiently and be cleared by regulators.

In the three years that it will likely take to get to the cusp of the clinic, Vesigen is also collaborating with researchers to show how ARMMs can get into tissues that no one can go to with implications in ocular and neurological diseases as well as cancer.

The Series A, co-led by Leaps by Bayer and Morningside Ventures and joined by Linden Lake Ventures and Alexandria Venture Investments, should fund the company until 2025, when Millman expects to have built out the team to 30.

Its exactly the kind of projects that his group likes to invest in early, Leaps by Bayer head Jrgen Eckhardt said, especially as big believers in the cell and gene therapy space who see delivery as the missing link. For Vesigen, it also opens up opportunities to find partners within the pharma giants network down the road.

While Millman is keen not to lose focus, he also isnt hiding ambitions to make this the next big one.

I saw all of the problems Alnylam I was there for three years, we couldnt get delivery. I worked very early at Celera and established collaborations with Ionis and again delivery was limited. I was helping set up Verve Therapeutics and again delivery of Cas9 was a problem, he said. And here was an eloquent solution. I was just pleased to be at the right place at the right time.

Here is the original post:
'Missing link': Bayer, Morningside help catapult a new kind of delivery tech to cell and gene therapy - Endpoints News

Two Cases Of West Nile Virus Confirmed In Greece Greek City Times – GreekCityTimes.com

By adminJuly 22, 2020Stem Cell Doctors

Greeces National Organisation of Public Health (EODY) has announced the first two laboratory confirmed cases of the West Nile virus infection for the 2020 transmission period, one in the Peripheral Unit of Xanthi (Municipality of Topeiros) and the other in the western Thessaly (Municipality of Karditsa).

As mentioned in an announcement from the EODY:

Cases of the West Nile virus infection occur in many countries worldwide, as well as in many European countries, on an annual basis. From 2010 onwards, cases occur almost every year (and) in our country, in various areas, during the summer and autumn months. Therefore, the recurrence of incidents during the current broadcast period was considered possible and expected. In May 2020, EODY informed health professionals nationwide about the need to be vigilant about the early diagnosis of cases.

As the epidemiology of the virus is determined by many factors, the areas where the virus will circulate cannot be safely predicted. Therefore, EODY recommends that you observe the individual protection measures against mosquitoes throughout Greece.

Recall that the West Nile virus is transmitted mainly by the bite of infected common mosquitoes, which are infected by infected birds (some species mainly wild birds). Infected people are not considered to transmit the virus to other mosquitoes.

The majority of people infected with the virus do not get sick at all or have only a mild illness, while very few people (<1% of those infected) develop a serious disease that affects the nervous system (mainly encephalitis or meningitis). Older people (over 50) are at greater risk of becoming seriously ill, as well as people with immunosuppression and chronic underlying diseases.

In order to timely implement targeted response and prevention measures, EODY -in each transmission period- conducts enhanced epidemiological surveillance of the disease, investigates cases immediately and is in constant communication and cooperation with the competent national, regional and local authorities.

More information about the West Nile virus and mosquito protection measures can be found on the EODY website, while also every Thursday a report with the current epidemiological data will be posted on the EODY website.

Read the original here:
Two Cases Of West Nile Virus Confirmed In Greece Greek City Times - GreekCityTimes.com

Citius Pharmaceuticals Forms Scientific Advisory Board for the Planned Development of its Proprietary Treatment for Acute Respiratory Disease…

By adminJuly 22, 2020Stem Cell Medicine

CRANFORD, N.J., July 22, 2020 /PRNewswire/ --Citius Pharmaceuticals, Inc. ("CITIUS") ("Company") (NASDAQ:CTXR), a specialty pharmaceutical companyfocused on developing and commercializing critical care drug products, announced today the formation of the Citius ARDS (Acute Respiratory Distress Syndrome) Scientific Advisory Board to provide the company expert guidance on its planned development of induced mesenchymal stem cells (iMSCs) under option from Novellus, Inc. to treat and reduce the severity of acute respiratory distress syndrome (ARDS) associated with COVID -19.

The ARDS Advisory Board consultants are: Michael A. Matthay, MD, Professor of Medicine and Anesthesia at the University of California at San Francisco (UCSF), a Senior Associate at the Cardiovascular Research Institute, and Associate Director of the Critical Care Medicine at UCSF. Dr. Matthay's basic research has focused on the pathogenesis and resolution of the acute respiratory distress syndrome (ARDS), with an emphasis on translational work and patient-based research, including clinical trials. Dr. Matthay's recent research has focused on the biology and potential clinical use of allogeneic bone marrow derived mesenchymal stromal cells (MSCs) for ARDS. He is currently leading the "Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (STAT)," a United States Department of Defense supported study of MSCs for ARDS.

Mitchell M. Levy, MD, Chief, Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, The Warren Alpert Medical School of Brown University, where he is Professor of Medicine. Dr. Levy also serves as Medical Director of the Medical ICU at Rhode Island Hospital. He has been an investigator on numerous pharmacologic and biologic trials intended to treat sepsis, cardiovascular and pulmonary pathology. He has expertise in trial design, clinical trial execution and trial management and is one of the three founding members of the Surviving Sepsis Campaign (SSC). Dr. Levy is Past-President of the Society of Critical Care Medicine (2009).

Lorraine B. Ware, MD, Professor of Medicine and Ralph and Lulu Owen Endowed Chair,Professor of Pathology, Microbiology and Immunology, Vanderbilt University;Director, Vanderbilt Medical Scholars Program. Dr. Lorraine Ware's comprehensive bench-to-bedside research program centers on the pathogenesis and treatment of sepsis and acute lung injury with a current focus on mechanisms of lung epithelial and endothelial oxidative injury by cell-free hemoglobin. Dr. Ware is also a lead investigator for the "Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (STAT)" study.

"We are extremely pleased to have been able to attract such a prestigious group of experts to advise and guide us in the Company's planned development of iMSC's for the treatment of ARDS" said Mr. Myron Holubiak, CEO of Citius. "These individuals are recognized opinion leaders and expert in the planning and execution of clinical trials in this therapeutic area. We will be seeking their advice in all phases of our clinical trial design."

About Citius Pharmaceuticals, Inc.Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit http://www.citiuspharma.com.

About Citius iMSCCitius's planned induced mesenchymal stem cell (iMSC) product is derived from a human induced pluripotent stem cell (iPSC) line generated using a proprietary non-immunogenic and non-viral mRNA-based (non-viral) reprogramming process. Unlike the MSCs derived from bone marrow, placenta, umbilical cord, or adipose tissue these proprietary iMSCs are based on a clonal process and therefore are genetically homogeneous and exhibit superior potency and higher cell viability. The Citius iMSC is an allogeneic (unrelated donor) mesenchymal stem-cell product manufactured by expanding material from an iMSC master cell bank. The master cell bank produces "off-the-shelf" iMSCs that are uniform as compared to MSCs using donor-sourced cells, which is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. In vitro studies demonstrate that iMSCs are shown to secrete higher levels of immunomodulatory proteins than donor-derived cells, and may reduce or prevent pulmonary injury associated with acute respiratory distress syndrome (ARDS) in patients with COVID-19.

About Acute Respiratory Distress Syndrome (ARDS)ARDS is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. ARDS is a rapidly progressive disease that occurs in critically ill patients most notably now in those diagnosed with COVID-19. ARDS affects approximately 200,000 patients per year in the U.S., exclusive of the current COVID-19 pandemic, and has a 30% to 50% mortality rate. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

Safe HarborThis press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.

Factors that could cause actual results to differ materially from those currently anticipated are: the risk of successfully negotiating within the option period a license agreement with Novellus, Inc. for our planned iMSCs therapy for ARDS; our need for substantial additional funds; risks associated with conducting clinical trials and drug development; the estimated markets for our product candidates and the acceptance thereof by any market; risks related to our growth strategy; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contact:Andrew Scott Vice President, Corporate Development (O) 908-967-6677 x105 [emailprotected]

SOURCE Citius Pharmaceuticals, Inc.

Home

Here is the original post:
Citius Pharmaceuticals Forms Scientific Advisory Board for the Planned Development of its Proprietary Treatment for Acute Respiratory Disease...

Potential Combination Therapy Discovered for Treating Head and Neck Squamous Cell Carcinoma – Genetic Engineering & Biotechnology News

By adminJuly 22, 2020Stem Cell Treatment

Head and neck squamous cell carcinoma (HNSCC) develops in the mucous membranes of the mouth, nose, and throat. It is an aggressive life-threatening disease associated with high mortality rates, and accounts for more than 90% of the cancers of the head and neck.

PD1 blockade-based combination therapy has been approved as a first-line treatment for HNSCC. However, the response rate remains relatively low, and patients with HNSCC eventually relapse. Now scientists at the UCLA Jonsson Comprehensive Cancer Center and UCLA School of Dentistry have revealed a potential new combination therapy to treat advanced head and neck squamous cell carcinoma. Using a mouse model, researchers found that using an anti-PD1 immunotherapy drug in combination with PTC209, an inhibitor that targets the protein BMI1, successfully stopped the growth and spread of the cancer, prevented reoccurrences, and eliminated cancer stem cells.

Their findings, BMI1 Inhibition Eliminates Residual Cancer Stem Cells after PD1 Blockade and Activates Antitumor Immunity to Prevent Metastasis and Relapse, is published in Cell Stem Cell.

PD1 blockade combined with chemotherapy has been approved for recurrent or metastatic head and neck cancer. However, response rates remain low and response duration is suggesting that this type of cancer might be resistant to PD1 blockade.

The researchers sought to overcome the resistance and had been studying the role of cancer stem cells and the protein BMI1. BMI1, a polycomb group (PcG) protein, plays a critical role in epigenetic regulation of cell differentiation and proliferation, and cancer stem cell self-renewal.

The researchers used a mouse model of HNSCC that mimicked human cancer development and metastasis, allowing them to perform lineage tracing of BMI1-positive cancer stem cells in an undisturbed tumor immune microenvironment. Then they tested whether BMI1 cancer stem cells could be eliminated by PD1 blockade-based combination therapy using both pharmacological and genetic inhibition of BMI1.

Here, we show that the combination treatment of anti-PD1 and cisplatin enriched BMI1+ CSCs in HNSCC while inhibiting HNSCC growth. In contrast, the pharmacological and genetic inhibition of BMI1 eliminated BMI1+ CSCs and enabled PD1 blockade therapy, resulting in the inhibition of metastatic HNSCC and prevention of HNSCC relapses, the researchers wrote.

BMI1 inhibition induced tumor cell-intrinsic immune responses by recruiting and activating CD8+ T cells along with eliminating BMI1 and cancer stem cells.

This is the first preclinical study to provide evidence that targeting BMI1 proteins enhances immunotherapy and eliminates cancer stem cells by activating antitumor immunity. This discovery holds promise for those with advanced head and neck cancers who are treated with PD1 blockade, but later become resistant to therapy.

See the article here:
Potential Combination Therapy Discovered for Treating Head and Neck Squamous Cell Carcinoma - Genetic Engineering & Biotechnology News

Eikonoklastes Therapeutics Closes Oversubscribed Seed Financing to Advance Next-Generation Tissue Factor (TF) Immunotherapies With Initial Focus on…

By adminJuly 22, 2020Stem Cell Treatment

CINCINNATI--(BUSINESS WIRE)-- Eikonoklastes Therapeutics, a preclinical stage biopharmaceutical company developing next-generation tissue factor (TF) immunotherapies for triple-negative breast cancer (TNBC) and several other diseases with unmet clinical need, today announced closing of an oversubscribed seed financing. Working with The Ohio State University Corporate Engagement Office and seed investor CincyTech, the company was formed to advance technology discovered and engineered in the lab of Dr. Zhiwei Hu, MD, PhD, and licensed from the Ohio State Innovation Foundation. CincyTech led the financing.

Eikonoklastes is developing novel immunotherapies that target tissue factor, a cell surface receptor that is prevalent in certain pathological cells-- but not healthy cells-- including a broad range of cancers with high unmet clinical need and high morbidity. The lead indication is triple- negative breast cancer, an aggressive cancer which accounts for 15% of all breast cancers, with an average mortality of ~18 months post diagnosis.

There is an urgent and critical need for a novel approach, said Bruce Halpryn, PhD, co-founder and CEO of Eikonoklastes. Eikonoklastes platform technology is designed for maximum efficacy and a superior safety profile, using targeted killing without the need for a toxic payload. This is a tremendous opportunity to treat numerous diseases.

Eikonoklastes L-ICON3 immune conjugate platform was discovered and engineered by scientific founder, Zhiwei Hu, MD, PhD, an early pioneer of tissue factor physiology, who has worked to leverage tissue factor as a highly specific and highly selective target for therapy. In his lab at Ohio State, Dr Hu has engineered molecules which attack three key components of the tumor microenvironment: the tumor cells, the disease neovasculature and tumor stem cells; activating the bodys natural immune reaction. These novel and proprietary molecules are the third generation of technology that Dr. Hu initially designed while at Yale University.

Dr. Hu has worked on several iterations of the technology that Eikonoklastes has licensed. We are grateful for his partnership and his dedication to discovery and innovation, said Scott Osborne, vice president of economic and corporate engagement at Ohio State.

The seed round will enable the company to complete a confirmatory in vivo I.V. efficacy study, to study I.V. pharmacokinetics, and to initiate manufacturing scaleup. The company will be headquartered in Cincinnati, OH.

We are impressed with the breadth of the opportunity, which has the potential to address critical needs for patient populations across a broad range of cancers and other diseases, said John Rice, PhD, Managing Director at CincyTech. We are also pleased to invest in the Eikonoklastes team, led by a seasoned and successful entrepreneur in Bruce Halpryn, with whom we had worked previously on Myonexus Therapeutics.

Halpryn and Chief Scientific/Medical Officer Mark Dato, MD, PhD, are both drug development industry veterans who worked together at P&G Pharmaceuticals. More recently Halpryn was COO of Myonexus Therapeutics, a gene therapy company also backed by CincyTech that was acquired by Sarepta Therapeutics in 2019. Halpryn then approached CincyTech about his next venture, co-founding Eikonoklastes with Sam Lee, MD, MBA, MPH, who will serve as Chief Business Officer. Details of the financing are undisclosed.

ABOUT EIKONOKLASTES THERAPEUTICS Eikonoklastes Therapeutics is advancing a new generation of tissue factor (TF) immunotherapies for the treatment of triple-negative breast cancer and other cancers and diseases with high morbidity and unmet clinical needs. Eikonoklastes proprietary molecules are engineered for maximum efficacy and a superior safety profile.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200722005443/en/

Longevity And Anti-Senescence Therapy Market Analysis, Trends, and Forecasts size- COVID-19 2023 – Cole of Duty

By adminJuly 22, 2020Stell Cell Research

Theglobal longevity and anti-senescence therapies marketshould grow from $329.8 million in 2018 to $644.4 million by 2023 with a compound annual growth rate (CAGR) of 14.3% during 2018-2023.

Report Scope:

The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023. The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.

Revenue forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.

Request for Report Sample:https://www.trendsmarketresearch.com/report/sample/11698

The report also includes a discussion of the major players performing research or the potential players across each regional longevity and anti-senescence therapy market. Further, it explains the major drivers and regional dynamics of the global longevity and anti-senescence therapy market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors and potential entrants in the global longevity and anti-senescence therapy market.

Report Includes:

71 data tables and 40 additional tables An overview of the global longevity and anti-senescence therapy market Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023 Country specific data and analysis for the United States, Canada, Japan, China, India, U.K., France, Germany, Spain, Australia, Middle East and Africa Detailed description of various anti-senescence therapies, such as senolytic drug therapy, gene therapy, immunotherapy and other stem cell therapies, and their influence in slowing down aging or reverse aging process

Coverage of various therapeutic drugs, devices and technologies and information on compounds used for the development of anti-ageing therapeutics A look at the clinical trials and expected launch of anti-senescence products Detailed profiles of the market leading companies and potential entrants in the global longevity and anti-senescence therapy market, including AgeX Therapeutics, CohBar Inc., PowerVision Inc., T.A. Sciences and Unity Biotechnology

Summary

Global longevity and anti-senescence therapy market deals in the adoption of different therapies and treatment options used to extend human longevity and lifespan. Human longevity is typically used to describe the length of an individuals lifetime and is sometimes used as a synonym for life expectancy in the demography. Anti-senescence is the process by which cells stop dividing irreversibly and enter a stage of permanent growth arrest, eliminating cell death. Anti-senescence therapy is used in the treatment of senescence induced through unrepaired DNA damage or other cellular stresses.

Global longevity and anti-senescence market will witness rapid growth over the forecast period (2018-2023) owing to an increasing emphasis on Stem Cell Research and an increasing demand for cell-based assays in research and development.

An increasing geriatric population across the globe and a rising awareness of antiaging products among generation Y and later generations are the major factors expected to promote the growth of global longevity and anti-senescence market. Factors such as a surging level of disposable income and increasing advancements in anti-senescence technologies are also providing traction to the global longevity and anti-senescence market growth over the forecast period (2018-2023).

According to the National Institutes of Health (NIH), the total geriatric population across the globe in 2016 was over REDACTED. By 2022, the global geriatric population (65 years and above) is anticipated to reach over REDACTED. An increasing geriatric population across the globe will generate huge growth prospectus to the market.

Senolytics, placenta stem cells and blood transfusions are some of the hot technologies picking up pace in the longevity and anti-anti-senescence market. Companies and start-ups across the globe such as Unity Biotechnology, Human Longevity Inc., Calico Life Sciences, Acorda Therapeutics, etc. are working extensively in this field for the extension of human longevity by focusing on study of genomics, microbiome, bioinformatics and stem cell therapies, etc. These factors are poised to drive market growth over the forecast period.

Global longevity and anti-senescence market is projected to rise at a CAGR of REDACTED during the forecast period of 2018 through 2023. In 2023, total revenues are expected to reach REDACTED, registering REDACTED in growth from REDACTED in 2018.

The report provides analysis based on each market segment including therapies and application. The therapies segment is further sub-segmented into Senolytic drug therapy, Gene therapy, Immunotherapy and Others. Senolytic drug therapy held the largest market revenue share of REDACTED in 2017. By 2023, total revenue from senolytic drug therapy is expected to reach REDACTED. Gene therapy segment is estimated to rise at the highest CAGR of REDACTED till 2023. The fastest growth of the gene therapy segment is due to the Large investments in genomics. For Instance; The National Human Genome Research Institute (U.S.) had a budget grant of REDACTED for REDACTED research projects in 2015, thus increasing funding to REDACTED for approximately REDACTED projects in 2016.

More Info of Impact [emailprotected]https://www.trendsmarketresearch.com/report/covid-19-analysis/11698

Originally posted here:
Longevity And Anti-Senescence Therapy Market Analysis, Trends, and Forecasts size- COVID-19 2023 - Cole of Duty

Pioneering Surgical Approach Could be Used as Treatment for Progressive Blindness – Technology Networks

By adminJuly 22, 2020Stell Cell Research

Read Time:

Dry age-related macular degeneration (dry AMD) poses a significant clinical challenge. It is one of the leading causes of progressive blindness, robbing millions of people over the age of 65 of their central vision, and it often hinders patients abilities to read books, drive and discern the faces of their loved ones. Although vitamin-based supplements may slow progression, no treatments currently exist. A team of physicians and scientists at the USC Dr. Allen and Charlotte Ginsburg Institute for Biomedical Therapeutics (Ginsburg Institute) saw in this situation an opportunity to innovate and pioneer a novel treatment approach for dry AMD patients. Theirs has been a feat of scientific and surgical prowess, and over a decade of their diligence and ingenuity has resulted in what may become the first FDA-approved treatment to transform the prospects of regaining vision for millions of patients.

The Ginsburg Institute team, led by vitreoretinal surgeons Amir Kashani, MD, PhD, associate professor of ophthalmology at the Keck School of Medicine, and Mark Humayun, MD, PhD, director of the Ginsburg Institute and co-director of the USC Roski Eye Institute, developed a stem cell-based retinal implant and accompanying surgical procedure to help restore vision to dry AMD patients. Their innovative approach and insights from their phase 1/2a clinical trial are described in the latest print issue of the American Academy of Ophthalmologys journal Ophthalmology Retina.

In practice, being able to get underneath the retina, which is only about a quarter of a millimeter thick, to physically replace the RPE cell layer is a challenging task, explains Kashani, who is lead author of the publication. Normally we dont operate underneath the retina. Its a place you generally try to avoid during surgery, so that has been a very novel, challenging aspect of delivering these stem cells.

There are very few tools for performing surgery within the subretinal space. Most available tools were designed 30 to 40 years ago, are relatively bulky and are generally meant to remove scar tissue or other lesions rather than insert anything into the subretinal space. The Ginsburg Institute team decided that the most promising option was to start fresh and design a brand-new tool to fit their purpose.

The surgeons worked with materials and design engineers at the Ginsburg Institute to create single-use forceps with an internal compartment to encapsulate the implant and a roller-style thumbwheel to deploy it. The implant itself is shaped much like a champagne bottle, and the forceps grab onto the narrow end. Rolling the implant into the devices compartment causes it to fold into a curved shape, and the surgeon can ultimately release it to lay flat inside the eye.

In pre-clinical models, creating a bleb alone proved insufficient; the surgeons had to innovate again and ultimately used water pressure to dissect one cell layer from another in a process called targeted hydrodissection. To monitor progress during surgery and prevent complications, the team utilized an advanced imaging technique called optical coherence tomography (OCT) to visualize the dissection at the cellular level. One part of our job was to make this a very doable surgery and I think we have achieved that with this study, Kashani says.

Without tools like OCT, it would be very difficult to visualize the damage we need to treat, Kashani explains. He emphasizes that in addition to using OCT intraoperatively, he sees a promising role for the technology to be used in earlier-stage AMD patients to monitor the progression of their geographic atrophy. Its not a standard of practice to use OCT and other diagnostic methods to detect early and subtle disease changes, but that may prove to be really important for classifying disease and treating it in the future.

Kashani adds that one of the most rewarding aspects of the entire clinical trial process has been working with his patients and witnessing their commitment to making this translation from research lab to clinical practice possible. None of this is happening by magic. Patients are volunteering, and theyre taking a chance for the sake of advancing medicine and potentially helping countless other patients down the road. We always appreciate that effort and we thank the patients and their families, too.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Original post:
Pioneering Surgical Approach Could be Used as Treatment for Progressive Blindness - Technology Networks

Global Cart Cell Therapy Market To Grow At A CAGR of 29.4% With The Emergence Of Immunotherapies In Medical Treatment – GlobeNewswire

By adminJuly 22, 2020Stem Cell Medical Center

July 22, 2020 08:41 ET | Source: Quince Market Insights

Pune, India, July 22, 2020 (GLOBE NEWSWIRE) -- The global cart cell therapy market size was valued at USD 355.1 million in 2018 and is anticipated to grow at a CAGR of 29.4% during the forecast period. For years, the foundations of cancer treatment were chemotherapy, surgery, and radiation therapy. With the development of targeted therapies like trastuzumab (Herceptin) and imatinib (Gleevec), drugs that target cancer cells have cemented themselves as standard treatments for many types of cancers.

Request For a Sample Copy Of This Research Report @ https://www.quincemarketinsights.com/request-sample-61563

But in recent years, immunotherapy has emerged as the "fifth pillar" of cancer treatment. The use of CAR T-cell clinical trials has captured the attention of researchers and the public alike because of the remarkable responses they have produced in both children and adults. Studies of CAR T-cell therapy in other blood cancers and treatment of solid tumors is also underway, researchers are exploring the application of CAR T-cell therapy.

The COVID-19 Impact on the Global Cart Cell Therapy Market

CAR-T and TCR-T therapies have revolutionized blood cancer treatment. Scientists at Duke-NUS Medical School are studying the potential of turning this approach for the treatment of COVID-19 patients.

Researchers suggest these immunotherapies might also be useful in treating SARS-CoV-2, the virus causing the current pandemic. Several organizations are also working on cell therapies for COVID-19. AlloVir and Baylor College of Medicine have partnered to develop an off-the-shelf therapy to target and treat the novel coronavirus.

The battle against COVID-19 is taking place across thousands of fronts in the U.S., from underfunded rural regional hospitals to the steel and glass high-rises of well-endowed university centers. What becomes clear when speaking with clinicians across the nation is that the effect of the pandemic on the delivery of CAR T-cell therapy depends on the type of center that provides it, as well as its location.

There were some initial delays providing CAR T-cell treatments at Mayo Clinic in Rochester, Minnesota, but they were short-lived and imposed in the name of patient safety as the institution looked to acquire an accurate diagnostic test to determine which patients had COVID-19.

CD19 to Lead the Target Antigen Segment of the Cart Cell Therapy Market

As per the current market scenario in 2018, the CD19 segment has covered the largest cart cell therapy market share and is projected to register a higher CAGR during the forecast period.

Besides, the growing need for integrated healthcare systems is responsible for the high demand for CD19 in the global cart cell therapy market.

Enquiry Before Buying This Report @ https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-61563

Cart Cell Therapy to Benefit Treatment of Blood Cancer Propelling the Growth of the Market

The application for the generation of revenues in the global cart cell therapy market is acute lymphoblastic leukemia, diffuse large b-cell lymphoma, and others. The acute lymphoblastic leukemia segment is predicted to account for the largest share. Cart Cell Therapy provides alternative therapeutic options for patients who failed to respond to conventional treatment or relapse for acute lymphoblastic leukemia which is a type of blood cancer.

Increasing Research Studies and Clinical Trials to Fuel the Growth of the Healthcare Segment

In 2018, healthcare accounted for the largest share of the end-user segment. As cart cell therapy improves clinical outcomes by helping to improve disease management. This will result in a shorter duration of hospitalization and overall physician observation hours.

North America Held a Major Market Share of the Global Cart Cell Therapy Market

North America holds a dominant position in the global cart cell therapy market. The region's dominance is attributable to favorable government policies for the prevention of disease and HCIT adoption, increasing funding for population health management, raising prevalence of chronic diseases, and the presence of well-developed healthcare infrastructure. For Instance, in 2010, the U.S. government implemented the Patient Protection and Affordable Care Act which encourages a high quality of care and reduces costs. The act has encouraged the creation of Accountable Care Organizations (ACOs), including the Medicare Shared Savings Program (MSSP).

Buy Now Complete Report @ https://www.quincemarketinsights.com/insight/buy-now/cart-cell-therapy-market/single_user_license

Companies Collaborate & Promote R&D along with Product Development

Cart Cell Therapy Market vendors are making substantial efforts in adopting advanced technologies essentially by allying and partnering that will help to facilitate the demand for Cart Cell Therapy.

Key participants include operating in the market include Bellicum Pharmaceuticals, Kite Pharma, Novartis AG, Mustang Bio, CARsgen Therapeutics, Sorrento Therapeutics, Autolus Therapeutics, Cellectis, Pfizer Inc., Legend Biotech, and others.

Search Important insights on Cart Cell Therapy Industry, By Region (Western Europe, North America, Eastern Europe, Middle East, Asia Pacific, and the Rest of the World), by End User (Pharmaceuticals, Hospital, Clinic and Others), By Target Antigen (CD22, CD19, and Others), and Application (Diffuse Large B-Cell Lymphoma, Acute Lymphoblastic Leukemia, and Others) Market Forecast & Assessment (2017-2028).

Browse Related Reports

Regenerative Medicine Market, By Type (Cell-Based Immunotherapy & Cell Therapy Products, Tissue-Engineered Products, Gene Therapy Products), Application (Wound Care, Musculoskeletal Disorders, Oncology, Ocular Disorders, Diabetes, Other Applications), and By Region (North America, Western Europe, Eastern Europe, Asia Pacific, Middle East, and the Rest of the World) Market Size & Forecasting (2017-2028)

https://www.quincemarketinsights.com/industry-analysis/regenerative-medicine-market/44444

Nerve Repair and Regeneration Market, By Products (Biomaterials, Nerve Conduits, Nerve Protectors, Nerve Wraps, Neurostimulation Devices) By Application (Neurorrhaphy, Nerve Grafting, Stem Cell Therapy, Neurostimulation Surgery),By Region (North America, Western Europe, Eastern Europe, Asia Pacific, Middle East, Rest of the World) Global Market Size & Forecasting(2016-2028)

https://www.quincemarketinsights.com/industry-analysis/nerve-repair-and-regeneration-market/59253

Cell Therapy And Tissue Engineering Market, By Type (Cell Therapy, Tissue Engineering, Others), By Application (Cell Defects, Genetic Diseases, Tissue Malignancy, Neurodegenerative Disease, Others), By Region (North America, Eastern Europe, Western Europe, Asia Pacific, Middle East, Rest Of The World) Market Size & Forecasting (2016-2028)

https://www.quincemarketinsights.com/industry-analysis/cell-therapy-and-tissue-engineering-market/60291

Autologous Cell Therapy Market, By Source (Bone Marrow, Epidermis), By Application (Neurology, Orthopedics, Cancer, Wound Healing, CVD, Autoimmune), By End User (Hospitals, Ambulatory Centers, Research Centers), By Region (North America, Eastern Europe, Western Europe, Asia Pacific, Middle East, Rest of the World) Market Size & Forecasting(2016-2028)

https://www.quincemarketinsights.com/industry-analysis/autologous-cell-therapy-market/60721

Culture Media Market, By Type (Lysogeny Broth, Chemically Defined Media, Classical Media, Serum-free Media, Specialty Media, Stem Cell Media, Custom Media Formulation, Others), By Application (Cancer Research, Biopharmaceuticals, Regenerative Medicine & Tissue Engineering, Stem Cell Technologies, Drug Discovery, Others), By Research Type (Cytogenetics, Cell Therapy, Others), By End User (Biotechnology & Pharmaceutical Industry, Academic Institute, Research Laboratory, Others), By Region (North America, Western Europe, Eastern Europe, Asia Pacific, Middle East, Rest of the World) Market Size & Forecasting (2016-2028)

https://www.quincemarketinsights.com/industry-analysis/culture-media-market/60933

About US

Quince Market Insights is a global market research and consulting company publishing syndicate studies as well as consulting assignments pertaining to markets that promise high growth opportunities in strategic future. We are dedicated team of analysts with strong base in technical expertise as well as thorough understanding of the market dynamics. Some of key areas expertise includes chemicals, advanced materials, construction, mining, food & agriculture, automotive, machines & equipment, and others. We analyze emerging trends in relatively nascent markets that promise high growth opportunities in future. We focus towards precision research practices that provide accurate market estimations and forecasts. This helps our clients to make proper estimations with regards to demand analysis, regional growth, major competitors, and dynamics of the market.

Read the rest here:
Global Cart Cell Therapy Market To Grow At A CAGR of 29.4% With The Emergence Of Immunotherapies In Medical Treatment - GlobeNewswire

Takeaways from the As loss to the Giants: why is the offense cold? – The Mercury News

By adminJuly 22, 2020Platelet Rich Plasma Injections

The Oakland As traveled across the Bay Bridge to play the second of a two-game exhibition series against the San Francisco Giants, losing 4-2.

This short and semi-sweet summer is over, and the As are clearly shaking off some rust heading into Opening Day at home against the Los Angeles Angels at the Oakland Coliseum.

Here are some takeaways from the last exhibition game of 2020.

As offense goes cold

The As scored all of four runs in these two losses. Stephen Piscotty hit a home run on Monday, and Chad Pinder hit a two-run double off the deep centerfield bricks at Oracle Park on Tuesday that the naked eye tells us was actually a home run.

Manager Bob Melvin challenged it, and the base hit call was upheld with very little explanation.

That the As faced 18 different pitchers in 18 innings probably didnt help ignite the offensive momentum. But, rare high points and a handful of competitive at bats aside, the As put together some rough plate appearances in these exhibition games.

We would have like to have better offense here the last couple games, just didnt happen, manager Bob Melvin said. We have a good offensive team, so its not concerning. Just didnt do a whole lot.

The As struck out eight times on Monday, 12 times on Tuesday. Through these two games, theyve collected six hits and eight walks.

If the As want to avoid a slow star thats plagued them in recent years, the sluggish offense theyve displayed certainly isnt promising.

Whos on second?

For all the hullabaloo surrounding second base during Spring Training 1.0 will it be Jorge Mateo? Tony Kemp? Franklin Barreto? Vimael Machin? Will there be a platoon? Will one player play the lions share? theres a chance Pinder could be the starting second baseman against Angels left-handed starter Andrew Heaney, Melvin said.

If not at second, expect Pinder somewhere in the lineup.

Pinder has been a standout at the plate during this camp, and hes had success against left-handed pitching: slashing .252/.313/.436 with a .748 OPS and 112 wRC+ against them.

If Pinder starts at second base, what does this mean for Barreto? He had one at bat in Tuesdays game, resulting in a strikeout. None on Monday.

Barreto also caught the teams attention at camp, where he hit two quick home runs off Frankie Montas and Liam Hendriks. Coaches have said that Barreto is in need of consistent at bats to show that his high ceiling he demonstrated in the minor leagues power at the plate, speed on the bases can translate to the big leagues.

Having too much talent at one position is a good problem to have. But, somehow the second base picture got a little more fuzzy. Maybe thats OK.

Fiers got the start at Oracle Park on Tuesday, allowing two home runs to Mike Yastrzemski to lead off the first inning and Alex Dickerson in the second inning on 67 pitches in 3.1 innings. He walked Pablo Sandoval before his exit in the fourth, and Sandoval scored on a sac fly off of Joakim Soria for Fiers third earned run.

The right-handed pitchers command was a tad off and he fumbled a few signs with catcher Austin Allen.

Allen, who was named to the 30-man roster as the backup catcher, is still adjusting to Fiers unpredictability and backwards pitching style.

I made it tough on myself, Fiers said after his start. I was just wild. Wasnt throwing the ball exactly where I wanted to. Just a little erratic.

Got another five days before games actually start, for me at least.

Fiers first meaningful start should come on Sunday, where hell go head-to-head with Angels phenom Shohei Ohtani. Fiers missed the first few days of camp taking extra precautions due to exposure to Jess Luzardo, who tested positive for the coronavirus prior to report day.

Because Fiers threw bullpens during the hiatus, he wasnt too far behind his fellow rotation mates. Even if this start left a sour taste in his mouth, Fiers curveball looked season ready.

Remember, Fiers curveball had one of the best vertical drops in baseball in 2019. His 70.7 vertical drop is 7.7 inches over the league average which ranks eighth in all of baseball.

Chris Bassitt looks ready to roll

Bassitt was a step behind the rest of the starters heading into camp. He hadnt faced live hitting during the hiatus like the others had.

He caught up quickly, and looked rotation ready dealing four innings with five strikeouts in Tuesdays game. His fastball hit 95 mph and he had command of his changeup and curveball.

Hell pitch fourth out of the rotation, on Monday against the Angels.

A.J. Puk and Jess Luzardo update

Puk traveled to Los Angeles to meet with Dr. Neal ElAttrache on Monday and received platelet-rich plasma and cortisone injections in his strained left shoulder, As manager Bob Melvin said Tuesday.

Puk is likely to be sidelined for two weeks, at least, and is resting for the next 48 hours.

The left-handed pitcher was slotted to start the season in the fifth spot of Oaklands rotation, but was placed on the 10-day IL. Right-handed pitcher Daniel Mengden will fill in for him in the rotation until Puks return from injury.

Jess Luzardo is slated to pitch in either the first or second game of the regular season, Melvin announced. Luzardo, who missed the first two weeks of camp after testing positive for coronavirus, is expected to come out of the bullpen and build his arm up to pitching three innings until he can be slotted into the rotation.

Luzardo pitched to Ramn Laureano in live batting practice prior to Mondays game against the San Francisco Giants.

Other notes

Read the rest here:
Takeaways from the As loss to the Giants: why is the offense cold? - The Mercury News